The role involves leading strategic sourcing and evaluation of later-stage external Hematology therapeutic assets from Phase 2 through marketed drugs.
Base: $308,000 - $377,000; Bonus/Equity: Incentive compensation and equity included; Benefits: Not specified
Must-have
Nice-to-have
Not specified